InStride raises $30 million in Series C with participation from .406 Ventures

  • InStride raised USD 30 million in a Series C funding round backed by new investors Echo Health Ventures, FMZ Ventures.
  • .406 Ventures participated alongside existing backers; InStride provides insurance-covered specialty care for youth with complex anxiety, OCD, related disorders.
  • Proceeds target expansion into new markets, deeper coverage in current markets.
  • InStride reported 2x revenue growth in 2025, with another 2x expected in 2026.
  • The company cited 97% overall clinical improvement for graduates, with 99%+ remaining out of hospital one year post-discharge.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. .406 Ventures LLC published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.